Taysha Gene Therapies (TSHA) Misses Q4 EPS by 58c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($0.99), $0.58 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $10 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• What Delta’s report tells investors in American and United
• Ategrity reports record Q2 results, names new CFO